The Role of microRNA-210 as a Biomarker for Assessing Pre-eclampsia Severity Insights and Implications

Pre-eclampsia remains a major cause of maternal and fetal complications worldwide. Identifying reliable biomarkers that reflect the severity of this condition can transform how clinicians manage affected pregnancies. Recent research has spotlighted microRNA-210 (miR-210) as a promising candidate. This blog post explores findings from a systematic review and meta-analysis on miR-210 levels in pre-eclampsia, highlighting its potential as a biomarker for disease severity, implications for clinical practice, and directions for future research.

MicroRNA-210 analysis under microscope

.

Understanding microRNA-210 and Pre-eclampsia

Pre-eclampsia is a pregnancy disorder characterized by high blood pressure and signs of damage to other organ systems, often the kidneys. It typically occurs after 20 weeks of gestation and can lead to serious, even fatal, complications for both mother and baby if untreated.

MicroRNAs are small, non-coding RNA molecules that regulate gene expression. Among them, microRNA-210 has attracted attention due to its role in cellular responses to low oxygen (hypoxia), a condition commonly observed in pre-eclamptic placentas. Elevated miR-210 levels have been linked to impaired placental function, which is central to pre-eclampsia development.

Key Insights from the Systematic Review and Meta-Analysis

The systematic review and meta-analysis compiled data from multiple studies measuring circulating miR-210 levels in pregnant women with pre-eclampsia compared to healthy controls. The analysis revealed several important points:

• Consistent Elevation of miR-210 in Pre-eclampsia: Across studies, miR-210 levels were significantly higher in women diagnosed with pre-eclampsia than in normotensive pregnant women.

  
  

• Correlation with Disease Severity: Higher miR-210 levels correlated with more severe forms of pre-eclampsia, including early-onset cases and those with greater clinical complications such as organ dysfunction.

  
  

• Potential as a Predictive Marker: Some studies indicated that elevated miR-210 could be detected before clinical symptoms appeared, suggesting a role in early diagnosis or risk stratification.

  
  

• Variability in Measurement Methods: Differences in sample types (plasma, serum, placental tissue) and detection techniques contributed to some heterogeneity in results, but the overall trend remained clear.

  
  

These findings support the hypothesis that miR-210 is not only involved in the pathophysiology of pre-eclampsia but also reflects its severity.

Implications for Clinical Practice and Patient Management

The ability to measure miR-210 levels reliably could offer several benefits in managing pre-eclampsia:

• Early Identification of High-Risk Patients: Detecting elevated miR-210 in early pregnancy could help identify women at risk for severe pre-eclampsia, allowing closer monitoring and timely interventions.

  
  

• Tailored Treatment Plans: Understanding the severity through miR-210 levels may guide decisions on hospitalization, medication, and timing of delivery to optimize outcomes.

  
  

• Non-invasive Monitoring: Since miR-210 can be measured in blood samples, it offers a less invasive alternative to placental biopsies or other diagnostic procedures.

  
  

• Complement to Existing Biomarkers: miR-210 could be combined with other markers like sFlt-1 and PlGF to improve diagnostic accuracy and prognostic assessments.

  
  

Clinicians should consider these potentials while acknowledging current limitations, such as standardization of testing and establishing clear clinical thresholds.

Potential for Future Research

While the evidence is promising, further research is needed to translate these findings into routine clinical use:

• Large-Scale Prospective Studies: More extensive, well-designed studies are necessary to confirm the predictive value of miR-210 and refine its role in clinical algorithms.

  
  

• Standardization of Assays: Developing uniform protocols for sample collection, processing, and miR-210 quantification will reduce variability and improve comparability.

  
  

• Mechanistic Studies: Investigating how miR-210 contributes to placental dysfunction and maternal symptoms could uncover new therapeutic targets.

  
  

• Integration with Multi-marker Panels: Research should explore how miR-210 performs alongside other biomarkers and clinical factors to enhance risk prediction models.

  
  

• Longitudinal Monitoring: Studying changes in miR-210 levels throughout pregnancy may provide insights into disease progression and response to treatment.

  
  

Summary

MicroRNA-210 shows strong potential as a biomarker for assessing the severity of pre-eclampsia. Elevated levels correlate with more severe disease and may allow earlier detection and better patient management. However, challenges remain in standardizing measurement and validating clinical applications. Continued research will be key to unlocking the full benefits of miR-210 in improving outcomes for mothers and babies affected by pre-eclampsia.

Clinicians and researchers should watch this space closely, as advances in miR-210 testing could soon become an important part of prenatal care. For patients, this means a future with more personalized and effective monitoring during pregnancy.

Reference:

MicroRNA‐210 level as a biomarker for pre‐eclampsia severity: A systematic review and meta‐analysis

Márai D, Virgens IPAd, Vincze Á, et al. MicroRNA-210 level as a biomarker for pre-eclampsia severity: A systematic review and meta-analysis. Int J Gynecol Obstet. 2026;00:1-11. doi:10.1002/ijgo.71145